# Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB

> **NCT03470233** · — · COMPLETED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 149 (actual)

## Conditions studied

- Multi-drug Resistant Tuberculosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03470233
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-25
- **Primary completion:** 2021-06-21
- **Final completion:** 2021-06-21
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2021-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03470233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03470233, "Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03470233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*